Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.
Brooklyn ImmunoTherapeutics (NYSE American: BTX) has appointed Dr. Howard J. Federoff as CEO and President effective April 16, 2021, succeeding Ronald Guido. Dr. Federoff aims to advance the clinical development of IRX-2, a cytokine-based therapy targeting solid tumors, alongside exploring new therapeutic agents. His extensive background in clinical and academic medicine, including previous leadership roles at UCI Health and Georgetown University, positions him as a strong asset for the company's objectives. Brooklyn's ongoing Phase 2A trial of IRX-2 in head and neck cancer has shown promising survival benefits.
- Appointment of Dr. Howard J. Federoff as CEO, bringing extensive experience.
- Leadership change aims to accelerate clinical development of IRX-2.
- IRX-2 shows overall survival benefit in ongoing Phase 2A head and neck cancer trial.
- None.
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn" or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer and President and a director as of 16 April 2021. Dr. Federoff succeeds Ronald Guido who was serving as Interim CEO and will remain on Brooklyn’s management team as Chief Development Officer.
“Dr. Federoff brings an unwavering focus on the patient as well as an outstanding record of clinical, academic and corporate achievement to Brooklyn ImmunoTherapeutics,” said Charles Cherington, Director of Brooklyn. “Dr. Federoff’s unparalleled record of professional accomplishments and experience will be a tremendous asset to Brooklyn ImmunoTherapeutics as we advance the clinical development of IRX-2 as well as explore potential new opportunities. We look forward to working with Dr. Federoff to bring new treatment options to patients living with cancer and other serious diseases.”
“Brooklyn’s IRX-2 product offers a significant opportunity to improve patient outcomes both as a monotherapy and in combination with other anti-cancer drugs including immune-oncology therapies,” said Dr. Federoff. “My top priorities will be the clinical advancement of IRX-2 in solid tumor indications as well as seeking opportunities to in-license new therapeutic agents that can extend and enhance the lives of patients fighting cancer and other serious diseases. This is an exciting time in oncology drug development and I believe that Brooklyn ImmunoTherapeutics will be a leader in advancing patient care.”
Dr. Federoff is a distinguished professor of neurology at the University of California, Irvine. He is the former CEO of UCI Health, vice chancellor for health affairs and dean of the UCI School of Medicine. Prior to joining UCI Health, Federoff was executive vice president of Health Sciences and executive dean at Georgetown University. Dr. Federoff has published more than 275 peer-reviewed and invited articles, and serves on editorial boards of five journals. He co-founded MedGenesis Therapeutix and Brain Neurotherapy Bio, both advancing therapeutics for neurologic diseases. He became CEO of the regenerative medicine company, Aspen Neuroscience, Inc, in San Diego. Aspen is developing an autologous iPSC drug product for Parkinson’s disease. Dr. Federoff chaired the NIH Recombinant DNA Advisory Committee, the NHLBI Gene Therapy Resource and the Board of the Association of the Academic Health Centers. He has served as an advisor/director for several companies. He is an elected Fellow of the American Association for the Advancement of Science and the National Academy of Inventors. He received his MD, MS and PhD in biochemistry from the Albert Einstein College of Medicine in New York. He completed his residency and clinical and research fellowships at Massachusetts General Hospital and Harvard Medical School.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance therapies using leading edge gene editing/cell therapy technology through its option agreement with Factor Bioscience/Novellus.
Brooklyn’s most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005284/en/
FAQ
Who is the new CEO of Brooklyn ImmunoTherapeutics?
What is the primary focus of Brooklyn ImmunoTherapeutics under the new CEO?
What progress has been made with IRX-2 in clinical trials?
What are the qualifications of Dr. Howard J. Federoff?
